In summary, our findings demonstrated that ANXA1 promoted tumor progression by activating EGFR signaling, which revealed that ANXA1 might be a prognostic predictor and underlying therapeutic target for BLCA. The gene discussed is EGFR; the disease is bladder transitional cell carcinoma.